Editorial Comment: Solifenacin treatment after intradetrusor injections with botulinum toxin in patients with neurogenic detrusor overactivity

Abstract

This prospective study evaluated whether adding solifenacin to the intradetrusor injection of botulinum toxin A (BoNT) could boost the effect of BoNT in patients with neurogenic detrusor overactivity (NDO) due to multiple sclerosis or spinal cord injury refractory to antimuscarinics alone (1). Thirty-nine patients who achieved total continence after BoNT injections were included in the analysis (group A: BoNT injections; group B: BoNT + solifenacin) and were followed for a minimum of 24 months. Data from urodynamic testing and questionnaire assessments before and 3 months after injections and reinjections were gathered.Reinjection was needed after a mean 8.2 months for group A and 11.7 months for group B. Patients receiving solifenacin also presented greater OABq score improvement (